Notably, cisplatin treatment (3 μg/mL) induced 8.229 ± 0.5217-fold upregulation of OLFM4 in treatment-naïve HNSCC-PDOs (Figure 1E), suggesting its potential role in cisplatin-resistance mechanisms. The gene discussed is OLFM4; the disease is head and neck squamous cell carcinoma.